TransMedics Group, Inc. $TMDX Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC reduced its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 342,791 shares of the company’s stock after selling 8,558 shares during the period. TransMedics Group accounts for about 1.1% of Emerald Advisers LLC’s investment portfolio, making the stock its 28th largest position. Emerald Advisers LLC owned 0.99% of TransMedics Group worth $34,077,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after purchasing an additional 113,817 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after buying an additional 2,903 shares during the period. Two Sigma Investments LP grew its stake in shares of TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after buying an additional 223,409 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after buying an additional 171,810 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on TMDX shares. Piper Sandler cut their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. Finally, Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $134.50.

Insider Transactions at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $75.74 on Tuesday. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The business has a 50-day moving average of $71.02 and a 200-day moving average of $105.87. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of 17.21 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. TransMedics Group’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1.92 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.